Drug Trial Radar · NCT06129539
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
56
Actual
Start
Jul 31, 2024
Primary completion
Oct 9, 2026
Study completion Feb 2028
Sponsor
- Lead sponsor
- Debiopharm International SAIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants with central precocious puberty (CPP).
Conditions
- Central Precocious Puberty
Interventions
Debio 4326Drug
Administered as an intramuscular (IM) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants With Suppression of Gonadotropin-Releasing Hormone Agonist Stimulated Serum Luteinizing Hormone (LH) to Less Than or Equal to (≤)5 International Units per Liter (IU/L)Time frame: Week 52 in Part A
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
Rady Children's Hospital - San Diego
San Diego, California
University of California San Francisco-Benioff Children's Hospital
San Francisco, California
Prisma Health Pediatric Endocrinology
Columbia, South Carolina
Instituto de Investigaciones Metabolicas (IDIM)
Buenos Aires, Argentina
Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada
Buenos Aires, Argentina
Centro de Investigaciones Medicas Mar del Plata
Mar del Plata, Argentina
Clinica Mayo de Urgencias Medicas Cruz Blanca S.R.L
San Miguel de Tucumán, Argentina
Hospital Da Criança de Brasília Jose Alencar
Brasília, Brazil
Hospital Universitario Walter Cantidio
Fortaleza, Brazil
Clínica de Endocrinologia e Metabologia Ltda
Lago Sul, Brazil
Nucleo de Pesquisa Clínica do Rio Grande do Sul-NPCRS
Porto Alegre, Brazil
CPQuali Pesquisa Clinica
São Paulo, Brazil
Irmandade Santa Casa de São Paulo
São Paulo, Brazil
Integral Pesquisa e Ensino
Votuporanga, Brazil
ENDOMET
Antofagasta, Chile
Hospital Clinico San Borja Arriaran (HCSBA)
Santiago, Chile
Christus Latam Hub Center of Excellence and Innovation S C
Monterrey, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.